1
|
Fonseca-González G, Alamilla-Sánchez M, García-Macas V, Herrera-Acevedo J, Villalobos-Brito M, Tapia-Rangel E, Maldonado-Tapia D, López-Mendoza M, Cano-Cervantes JH, Orozco-Vázquez J, Timarán-Montenegro D, Cortés-Martínez S, Escarela-Serrano M, Muñoz-López S, Montiel-López L, Mondragón-Terán P, Suárez-Cuenca JA. Impact of plasmapheresis on severe COVID-19. Sci Rep 2023; 13:163. [PMID: 36599875 PMCID: PMC9812351 DOI: 10.1038/s41598-022-25930-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Accepted: 12/07/2022] [Indexed: 01/05/2023] Open
Abstract
The clinical course of COVID-19 may show severe presentation, potentially involving dynamic cytokine storms and T cell lymphopenia, which are leading causes of death in patients with SARS-CoV-2 infection. Plasma exchange therapy (PLEX) effectively removes pro-inflammatory factors, modulating and restoring innate and adaptive immune responses. This clinical trial aimed to evaluate the impact of PLEX on the survival of patients with severe SARS-CoV-2 and the effect on the cytokine release syndrome. Hospitalized patients diagnosed with SARS-CoV-2 infection and cytokine storm syndrome were selected to receive 2 sessions of PLEX or standard therapy. Primary outcome was all-cause 60-days mortality; secondary outcome was requirement of mechanical ventilation, SOFA, NEWs-2 scores modification, reduction of pro-inflammatory biomarkers and hospitalization time. Twenty patients received PLEX were compared against 40 patients receiving standard therapy. PLEX reduced 60-days mortality (50% vs 20%; OR 0.25, 95%CI 0.071-0.880; p = 0.029), and this effect was independent from demographic variables and drug therapies used. PLEX significantly decreased SOFA, NEWs-2, pro-inflammatory mediators and increased lymphocyte count, accompanied with a trend to reduce affected lung volume, without effect on SatO2/FiO2 indicator or mechanical ventilation requirement. PLEX therapy provided significant benefits of pro-inflammatory clearance and reduction of 60-days mortality in selected patients with COVID-19, without significant adverse events.
Collapse
Affiliation(s)
- G. Fonseca-González
- grid.420239.e0000 0001 2113 9210Department of Nephrology, Transplantation and Extracorporeal Therapies, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - M. Alamilla-Sánchez
- grid.420239.e0000 0001 2113 9210Department of Nephrology, Transplantation and Extracorporeal Therapies, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - V. García-Macas
- grid.420239.e0000 0001 2113 9210Department of Nephrology, Transplantation and Extracorporeal Therapies, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - J. Herrera-Acevedo
- grid.420239.e0000 0001 2113 9210Department of Nephrology, Transplantation and Extracorporeal Therapies, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - M. Villalobos-Brito
- grid.420239.e0000 0001 2113 9210Department of Internal Medicine, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - E. Tapia-Rangel
- grid.420239.e0000 0001 2113 9210Department of Therapeutic and Diagnostic Radiology, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - D. Maldonado-Tapia
- grid.420239.e0000 0001 2113 9210Department of Nephrology, Transplantation and Extracorporeal Therapies, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - M. López-Mendoza
- grid.420239.e0000 0001 2113 9210Department of Nephrology, Transplantation and Extracorporeal Therapies, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - J. H. Cano-Cervantes
- grid.420239.e0000 0001 2113 9210Department of Nephrology, Transplantation and Extracorporeal Therapies, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - J. Orozco-Vázquez
- grid.420239.e0000 0001 2113 9210Department of Therapeutic and Diagnostic Radiology, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - D. Timarán-Montenegro
- grid.420239.e0000 0001 2113 9210Department of Therapeutic and Diagnostic Radiology, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - S. Cortés-Martínez
- grid.420239.e0000 0001 2113 9210Hormone Laboratory, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - M. Escarela-Serrano
- grid.420239.e0000 0001 2113 9210Department of Internal Medicine, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - S. Muñoz-López
- grid.420239.e0000 0001 2113 9210Department of Internal Medicine, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - L. Montiel-López
- grid.420239.e0000 0001 2113 9210Department of Internal Medicine, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - P. Mondragón-Terán
- grid.420239.e0000 0001 2113 9210Clinical Research Department, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - J. A. Suárez-Cuenca
- grid.420239.e0000 0001 2113 9210Clinical Research Department, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| |
Collapse
|
2
|
Robledo-Nolasco R, Godínez-Montes de Oca A, Zaballa-Contreras JF, Suárez-Cuenca JA, Mondragón-Terán P, Rubio-Guerra AF, Meléndez-Alcántara MA. Efficacy of Change to New P2Y12 Receptor Antagonists in Patients High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention. Clin Appl Thromb Hemost 2014; 21:619-25. [DOI: 10.1177/1076029614564208] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Selective intensification of platelet inhibition may improve high on treatment platelet reactivity (HPR). We evaluated the efficacy of dual-antiplatelet therapy, including clopidogrel (CPG), compared to new P2Y12-receptor antagonists in patients with HPR undergoing percutaneous coronary intervention, regarding the outcome of composite major adverse cardiac events (MACEs, including death, acute coronary syndrome [ACS], and stent restenosis). The presence of HPR (71 of 181 patients) almost doubled the risk of MACEs. The new antiplatelet agent reduced MACEs (45.8%, 26%, and 16.7% for CPG, prasugrel, and ticagrelor [TGL]; RR 0.36; 0.13-0.98, P = .03, TGL), specifically in patients with ACS. Failure to reduce HPR after the antiplatelet change and diabetes were independent predictors for MACEs. The HPR was early and effectively reduced after changing the antiplatelet therapy, but the intensity of this reduction did not significantly decrease the risk of MACEs. These findings support the benefit of HPR-guided intensification of platelet inhibition. Whether the intensity of this reduction improves the patient’s clinical outcomes deserves further investigation.
Collapse
Affiliation(s)
- Rogelio Robledo-Nolasco
- Servicio de Hemodinamia, Departamento de Cardiologíay, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - A. Godínez-Montes de Oca
- Servicio de Hemodinamia, Departamento de Cardiologíay, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - J. F. Zaballa-Contreras
- Servicio de Hemodinamia, Departamento de Cardiologíay, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - J. A. Suárez-Cuenca
- División de Investigación Biomédica y Clínica, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
- Clinical Research Unit, Hospital General de Ticomán and Mexican Group for Basic and Clinical Research in Internal Medicine, Mexico City, Mexico
| | - P. Mondragón-Terán
- División de Investigación Biomédica y Clínica, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| | - A. F. Rubio-Guerra
- Clinical Research Unit, Hospital General de Ticomán and Mexican Group for Basic and Clinical Research in Internal Medicine, Mexico City, Mexico
| | - M. A. Meléndez-Alcántara
- Servicio de Hemodinamia, Departamento de Cardiologíay, Centro Médico Nacional “20 de Noviembre” ISSSTE, Mexico City, Mexico
| |
Collapse
|
3
|
Hernández-Muñoz R, Díaz-Muñoz M, Suárez-Cuenca JA, Trejo-Solís C, López V, Sánchez-Sevilla L, Yáñez L, De Sánchez VC. Adenosine reverses a preestablished CCl4-induced micronodular cirrhosis through enhancing collagenolytic activity and stimulating hepatocyte cell proliferation in rats. Hepatology 2001; 34:677-87. [PMID: 11584363 DOI: 10.1053/jhep.2001.27949] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Cirrhosis is one of the most common causes of mortality worldwide, because hepatic dysfunction constitutes a potentially lethal condition. Having demonstrated the hepatoprotective effect of adenosine against CCl(4)-induced cirrhosis, the present study was aimed at assessing adenosine's effect on an already-established micronodular cirrhosis. Chronic administration of CCl(4) (10 weeks) induced a cirrhotic state, characterized by increased liver fibronectin and collagen types I and III content, enhanced expression of alpha-1 (I) collagen mRNA, portal hypertension, and liver dysfunction. After CCl(4) discontinuation (5 weeks), increased persitance of alpha-1 (I) collagen mRNA expression and deposition, enhanced proline incorporation into collagen and prolyl hydroxylase activity evidenced active fibrogenesis. Several weeks after CCl(4) withdrawal, deposited collagen showed an enhanced type I/III ratio, which was associated with deficient collagenolytic activity in cirrhotic livers. Liver expression of some metalloproteinases (MMPs) and of tissue inhibitors of MMPs (TIMPs) also indicated decreased collagen breakdown in cirrhotic livers. Parameters indicative of oxidative stress (mainly protein oxidation) were persistently augmented. These events were coincident with diminished regenerative capacity of the cirrhotic liver. Intraperitoneal adenosine administration to CCl(4)-induced cirrhotic rats blocked active fibrogenesis and increased the collagen degradation (most probably by decreasing liver TIMPs levels), normalizing collagen-type ratios. In addition, the nucleoside promoted an effective hepatocyte's proliferation in the cirrhotic liver and accelerated normalization of parameters indicative of liver function and oxidative stress. Thus, adenosine readily reversed an experimental cirrhosis through stimulating liver collagenolytic and proliferative capacities, as well as by accelerating functional recovery.
Collapse
Affiliation(s)
- R Hernández-Muñoz
- Departamento de Biología Celular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México
| | | | | | | | | | | | | | | |
Collapse
|